What is the official website of Novartis US ?

The official website of Novartis US is https://www.novartis.us/.

What is Novartis US's cybersecurity risk score?

Novartis US has an AI-generated cybersecurity risk score of 776 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis US experienced?

According to Rankiteo, Novartis US currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis US been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis US has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis US have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis US is not certified under SOC 2 Type 1.

Does Novartis US have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis US does not hold a SOC 2 Type 2 certification.

Does Novartis US comply with GDPR ?

According to Rankiteo, Novartis US is not listed as GDPR compliant.

Does Novartis US have PCI DSS certification ?

According to Rankiteo, Novartis US does not currently maintain PCI DSS compliance.

Does Novartis US comply with HIPAA ?

According to Rankiteo, Novartis US is not compliant with HIPAA regulations.

Does Novartis US have ISO 27001 certification ?

According to Rankiteo,Novartis US is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis US operate in ?

Novartis US operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis US have ?

Novartis US employs approximately None employees people worldwide.

Does Novartis US own any subsidiaries ?

Novartis US presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis US have ?

Novartis US's official LinkedIn profile has approximately 201,696 followers.

What is the NAICS classification code for Novartis US ?

Novartis US is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis US have a Crunchbase profile ?

No, Novartis US does not have a profile on Crunchbase.

Does Novartis US have a LinkedIn profile ?

Yes, Novartis US maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-us.

How many cybersecurity incidents has Novartis US experienced ?

As of August 23, 2026, Rankiteo reports that Novartis US has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis US have ?

Novartis US has an estimated 5,730 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis US faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Cyber Attack and Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis US

Boost Score +25 with badge (5 left)

776

/1000

Fair

801

/1000

Good

Novartis US Vendor Cyber Rating & Cyber Score

novartis.us

Add Your Compliance Badge

We are an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. See our community guidelines: https://go.novartis.social/4bqbjuA

Novartis US A.I CyberSecurity Scoring

Scoring History

Novartis US

Novartis US CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis US

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis US Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis US

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis US in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis US in 2026.

Incident Types Novartis US vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis US in 2026.

Incident History - Novartis US (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis US Subsidiaries

Novartis US

Pharmaceutical Manufacturing

Website: https://www.novartis.us/

Company Size: 10,001+ employees

Novartis Gene TherapiesBiotechnology Research

NovartisPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Loading…

Novartis US Similar Companies

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Loading…

NEWS

Novartis US CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 22, 2026 12:19 AM

Novartis Gets Win On Entresto Patent Tied To Earlier Ruling

A Delaware federal judge found Wednesday that MSN Pharmaceuticals Inc. infringed a patent covering Novartis Pharmaceuticals Corp.

Read Article

January 20, 2026 10:10 AM

Novartis expects to eliminate US tariff exposure by mid‑2026, CEO tells CNBC

Novartis CEO Vas Narasimhan told CNBC on Tuesday he expects the drugmaker's agreement with the U.S. government and its expanding...

Read Article

January 20, 2026 10:10 AM

Novartis’ U.S. deal could shield it from tariffs, CEO tells CNBC

Swiss pharmaceutical giant Novartis expects to "not really" be exposed to tariffs by the middle of the year, CEO Vas Narasimhan told CNBC at...

Read Article

January 20, 2026 10:00 AM

Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Novartis AG is placed ninth on our list among the best cancer stocks.

Read Article

December 23, 2025 11:58 AM

Novartis, US Government Reach Agreement to Reduce Drug Prices

Revised Read about the agreement between Novartis and the US Government to reduce drug prices. A crucial step for medications like Entresto and Multiple...

Read Article

December 22, 2025 08:00 AM

Novartis, US government reach agreement to lower drug prices

Novartis has reached an agreement with the US government with the aim of reducing the price of innovative medicines and supporting continued...

Read Article

December 18, 2025 08:00 AM

Novartis, Roche back US efforts to lower drug costs amid talk of pricing deal

Swiss pharma giants Novartis and Roche on Thursday backed U.S. efforts to lower the cost of drugs and are working with the Trump...

Read Article

December 17, 2025 08:00 AM

Novartis, Roche near US drug price deal, Bloomberg News reports

The White House is set to announce drug pricing deals with pharmaceutical giants Novartis and Roche Holding as soon as Friday,...

Read Article

December 09, 2025 08:00 AM

Novartis AG (NVS) Announces US FDA Approval of Itvisma®

Novartis AG (NYSE:NVS) is one of the Most Undervalued Stocks to Buy Right Now. On November 24, the company announced that the US FDA...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-78122

SUMMARY

docker-socket-proxy fails to properly gate read endpoints in the /containers Docker API namespace when the CONTAINERS environment variable is set. Attackers can use GET requests to /containers/{id}/archive, /containers/{id}/export, /containers/{id}/logs, and /containers/{id}/top to read arbitrary files and download entire container filesystems as tar archives.

Published

Date2026-08-22

Updated

Date2026-08-22

RISK INFORMATION (Score: 7.4)

cvss3

Base Score: 7.4

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:C/C:H/I:N/A:N

cvss4

Base Score: 8.3

Complexity: LOW

CVSS:4.0/AV:A/AC:L/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

2.8

REFERENCES

CVE-2026-78049

SUMMARY

A vulnerability has been found in Systerel S2OPC up to 1.7.3. Impacted is the function SOPC_NodeMgtHelperInternal_AddVariableNodeAttributes of the file src/ClientServer/address_space/internal/sopc_node_mgt_helper_internal.c of the component AddNodes Service. The manipulation of the argument UserAccessLevel leads to out-of-bounds read. It is possible to initiate the attack remotely. A high degree of complexity is needed for the attack. The exploitability is considered difficult. The exploit has been disclosed to the public and may be used. The identifier of the patch is aafbd37d381b618312ebdf5ddf57027f62c14fdd. It is suggested to install a patch to address this issue.

Published

Date2026-08-22

Updated

Date2026-08-22

RISK INFORMATION (Score: 3.7)

cvss2

Base Score: 2.6

Complexity: HIGH

AV:N/AC:H/Au:N/C:N/I:N/A:P

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 2.9

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2026-12999

SUMMARY

The Infineon Airoc Wi-Fi driver's transmit callback airoc_mgmt_send() in drivers/wifi/infineon/airoc_wifi.c allocates a net_buf from the fixed airoc_pool for every outbound packet. When whd_network_send_ethernet_data() returns a synchronous failure, the underlying WHD library does not take ownership of the buffer, but the pre-fix driver returned -EIO without releasing it. Each failed transmit therefore permanently leaks one buffer from the pool. airoc_pool is small and fixed (AIROC_WIFI_TX_PACKET_POOL_COUNT + AIROC_WIFI_RX_PACKET_POOL_COUNT, default 20 buffers) and is shared by WHD's whd_host_buffer_get callback for both transmit and receive. Once enough send failures have leaked the pool dry, airoc_wifi_host_buffer_get() returns WHD_BUFFER_ALLOC_FAIL for all subsequent allocations, so both transmit and the WHD-driven receive path fail and Wi-Fi connectivity is lost until the device is rebooted. The leak occurs only on the transmit error path. A Wi-Fi-adjacent attacker can influence the conditions that cause synchronous send failures (for example by deauthenticating/disassociating the station while the local stack continues to attempt transmits), and ordinary transient failures over the device's lifetime accumulate toward the same state. Reliable on-demand triggering is of high complexity and the impact is availability-only, but the resulting denial of service is permanent and non-recoverable without a reboot. The fix releases the buffer with airoc_wifi_buffer_release() on the failure branch, returning it to the pool. The commit also removes a redundant k_sem_give() in airoc_mgmt_disconnect(); because data->sema_common is a binary semaphore (limit 1) the duplicate give merely saturated at 1 and had no security impact.

Published

Date2026-08-22

Updated

Date2026-08-22

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: HIGH

CVSS:3.1/AV:A/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

1.6

REFERENCES

CVE-2026-74733

SUMMARY

In the Linux kernel, the following vulnerability has been resolved: gpio: pca953x: fix pca953x_irq_bus_sync_unlock regmap lock Locking is disabled in the regmap config as this driver uses its own lock. This means that all calls to regmap functions (read or write) must hold the i2c_lock. The function pca953x_irq_bus_sync_unlock() did not do this, and it was therefore possible that multiple threads could cause an incorrect register to be read/written. A previous patch partly fixed this, but only protected the write to the interrupt mask register, and not the read from the direction register.

Published

Date2026-08-22

Updated

Date2026-08-22

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-74732

SUMMARY

In the Linux kernel, the following vulnerability has been resolved: drm/amd/display: Check for tg ops in dce110_set_avmute Some older DCE timing generators do not implement is_tg_enabled in their ops table. Calling it unconditionally when waiting for AV mute frames causes a NULL pointer dereference on Southern Islands dGPUs when turning the display off over HDMI. Check that tg and the required ops exist before waiting for frames. (cherry picked from commit 2686a0c0aaa07bec2e24131835cf27b5fd4935a5)

Published

Date2026-08-22

Updated

Date2026-08-22

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…